VRX is going to lay off 28,000 Americans? Will SEC approve insider trading, and next MCI in offing?
Meanwhile, Valeant has become a serial acquirer, entering into 100 acquisitions or joint ventures since its chief executive, Michael Pearson, joined the company in 2008. The modus operandi has been to slash expenses, including those for research and development, and staff. If the Allergan acquisition goes through, about 20% of the combined companies' staff of 28,000 will be cut, Pearson said.